Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Pantazis-Michail Voutsinas"'
Autor:
Dimitris Basoulis, Pantelis Avramopoulos, Maria Aggelara, Georgios Karamanakos, Pantazis-Michail Voutsinas, Amalia Karapanou, Mina Psichogiou, Michalis Samarkos, Foteini Ntziora, Nikolaos V. Sipsas
Publikováno v:
Canadian Respiratory Journal, Vol 2023 (2023)
Background. High-flow nasal cannula (HFNC) is an oxygen delivery method shown to reduce the risk of intubation and mortality in patients with type 1 respiratory failure. The ROX-index score can predict HFNC failure. This study aims to evaluate sequen
Externí odkaz:
https://doaj.org/article/2a47c13d88d94093a708f1dad3bfdf8b
Autor:
Dimitrios Basoulis, Aristeidis Tsakanikas, Aikaterini Gkoufa, Aikaterini Bitsani, Georgios Karamanakos, Elpida Mastrogianni, Vasiliki E. Georgakopoulou, Sotiria Makrodimitri, Pantazis-Michail Voutsinas, Panagiota Lamprou, Athanasios Kontos, Stathis Tsiakas, Maria N. Gamaletsou, Smaragdi Marinaki, Nikolaos V. Sipsas
Publikováno v:
Viruses, Vol 15, Iss 7, p 1515 (2023)
Background: Nirmatrelvir/ritonavir (NMV/r) and three-day course remdesivir (3RDV) have been approved as early treatments for COVID-19 outpatients not requiring supplemental oxygen. Real-life data on the efficacy of antivirals among immunocompromised
Externí odkaz:
https://doaj.org/article/aada0173fed046cbb59ed18a5a4ab658
Publikováno v:
Viruses, Vol 15, Iss 2, p 577 (2023)
The COVID-19 pandemic has been a global medical emergency with a significant socio-economic impact. People with HIV (PWH), due to the underlying immunosuppression and the particularities of HIV stigma, are considered a vulnerable population at high r
Externí odkaz:
https://doaj.org/article/471aba0fd1294de6a0de63c3f574d0ea
Autor:
Sipsas, Dimitrios Basoulis, Aristeidis Tsakanikas, Aikaterini Gkoufa, Aikaterini Bitsani, Georgios Karamanakos, Elpida Mastrogianni, Vasiliki E. Georgakopoulou, Sotiria Makrodimitri, Pantazis-Michail Voutsinas, Panagiota Lamprou, Athanasios Kontos, Stathis Tsiakas, Maria N. Gamaletsou, Smaragdi Marinaki, Nikolaos V.
Publikováno v:
Viruses; Volume 15; Issue 7; Pages: 1515
Background: Nirmatrelvir/ritonavir (NMV/r) and three-day course remdesivir (3RDV) have been approved as early treatments for COVID-19 outpatients not requiring supplemental oxygen. Real-life data on the efficacy of antivirals among immunocompromised
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=multidiscipl::4b78aed834e2bcf290cdbc4abb86a808